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The sera of 13 patients with mixed cryoglobulinemia 
were examined for the presence of circulating immune 
complexes with the 1251-C1q binding assay before and 
after precipitation of cryoglobulins. All 13 patients had 
increased C1q binding activity (>10%) prior to cryopre-
cipitation (mean C1q binding activity = 69%) and 10 of 
13 had increased C1q binding activity after precipitation 
and removal of cryoglobulin (mean C1q binding activity 
= 41 %). Decrements in serum C1q binding activity 
caused by cryoprecipitation ranged from minimal to 
marked (1-73%). Since all of these sera contained IgM 
rheumatoid factor, 7 were treated with 2-mercaptoeth-
anol, known to dissociate 198 IgM into its subunits, and 
then tested for C1q binding activity and rheumatoid 
factor. 2-mercaptoethanol eliminated rheumatoid factor 
activity in all cases, but C1q binding activity remained 
elevated in 6 of 7 sera, thus indicating the presence of 
immune complexes distinct from 198 IgM rheumatoid 
factor complexes. By contrast absorption of 9 mixed 
cryoglobulinemia sera with solid-phase protein A re-
sulted in the disappearance of immune complex-like ma-
terial from the test sera, suggesting that IgG is a major 
constituent of the C1q binding material. Addition of 
eluates from the solid phase protein A to normal sera 
resulted in the appearance of increased C1q binding 
activity. Hepatitis B surface antigen was detected in the 
protein A eluates of two of six patients tested, and anti-
body to hepatitis B surface antigen was detected in the 
protein A eluate of a third patient. These findings indi-
cate that in addition to cryoglobulins patients with 
mixed cryoglobulinemia have circulating immune com-
plexes that are noncryoprecipitable. The immune com-
plexes contain predominantly lgG and are, in most cases, 
distinct from 198 lgM rheumatoid factor complexes. In 
some cases the immune complexes may contain hepatitis 
B surface antigen or antibody. 
Mixed cryoglobulinemia (MC) is a clinical syndrome char-
acterized by necrotizing vasculitis with purpura, arthralgias or 
arthritis, liver disease and often glomerulonephritis in patients 
who do not have a well-defined connective tissue disease or a 
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Abbreviations: 
BA: binding activity 
HGG: human gamma globulin 
IEP: immunoelectrophoresis 
MC: mixed cryoglobulinemia 
2-ME: 2-mercaptoethanol 
NHS: normal human serum 
PBS: phosphate buffered saline 
PEG: polyethylene glycol 
RF: rheumatoid factor 
lymphorecticular neoplasm. All patients have cold precipitating 
proteins in their sera, which are usually composed of IgM and 
IgG antibodies. The IgM has rheumatoid factor (RF) activity 
and binds to the polyclonal IgG to form a cold insoluble immune 
complex. Histologic examination of involved skin reveals leu-
kocytoclastic angiitis with perivascular polymorphonuclear leu-
kocytes, nuclear dust, endothelial swelling, fibrinoid degenera-
tion and extravasation of red blood cells. A pathogenic role for 
these complexes is suggested by systemic hypocomplemen-
temia, and immunofluorescence studies demonstrating the pres-
ence of immunoglobulin and/ or complement in vessel walls of 
lesional skin [1-6]. In addi tion a high percentage of patients 
have evidence of liver dysfunction. Recently, Levo et a l dem-
onstrated that many patients with MC, have hepatitis B smface 
antigen (HBsAg) in their serum and/ or cryoprecipitates and 
suggested that in1mune complexes containing hepatitis virus 
might play a role in the pathogenesis of mixed cryoglobulinemia 
[7]. Thus several lines of evidence suggest that circulating 
immune complexes may play an important role in the patho-
physiology of this disease. We have examined the sera of 13 
patients with MC for evidence of circulating immune complexes 
using the 125 1-Clq binding assay and have characterized the 
immune complexes with regard to cryoprecipitabili ty, relation-
ship to RF, predominant antibody class, and have identified 
HBsAg in preparations of partially pmified in1mune complexes 
from some of these patients. 
MATERIALS AND METHODS 
Patient Selection 
Thirteen patients with mixed cryoglobulinemia unassociated with 
any underlying disease were studied. There were 4 males and 9 females, 
ranging in age from 31 to 69 yr. E leven patients had necrotizing 
vasculitis with palpable purpura, and a ll had ar thri t is or arthralgias, 
and moderate to marked splenomegaly. Five had biopsy proven diffuse 
proliferative glomerulonephritis, and 7 had liver disease, as assessed by 
hepatomegaly, abnormal liver function tests or liver biopsy. All had 
significant a mounts of IgG-IgM containing cryoglobulins and rheu-
matoid factor in their serum. Four had either the hepatitis B surface 
ant igen or antibody to the surface antigen in their serum or cryoprecip-
itate. 12 of 13 patients had a history of hypocomplementemia. 
Purification of Human Clq 
Clq was purified from freshly drawn human blood according to the 
method of Yonemasu and Stroud [8). Pw·ity was checked by double 
diffusion in gel against rabbit antisera to human Clq , IgG, IgA, lgM 
and C3; immunoelectrophoresis (IEP) against these same rabbit anti-
sera as well as against a nti-whole human serum was a lso performed as 
was radial immunodiffusion on LC-partigen plates (Behring Diagnos-
tics). No contaminating IgG, IgA, IgM or C3 was found and the Clq 
preparation gave a single precipitin line against anti-whole human 
serum on IEP which was identical to that against anti-human Clq. 
Radio iodination of Clq 
Purified human Clq was radiolabeled with 12"1 with the Bolton-
Hunter reagent (iodinated p-hydroxyphenylpropionic acid, N-hydroxy-
succinimide ester) (New England Nuclear, Boston, MA) . Clq at a 
concentration of 0.5 mg/ ml in 0.75 M NaCl, 0.01 M EDTA and 0.02 M 
sodium acetate, pH 7.5, was thawed and centrifuged at 20,000 g for 30 
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min to remove aggregates. Two hundred and fifty microcur ies of 
Bolton-Hunter reagen t were introduced into the bottom of a clean glass 
tube and evaporated under gent ly !lowing nitrogen gas. 0.5 ml of bicine 
buffer N , N-bis (2- hydroxyethyl) glycine, pH 8.3 was added, and stirred 
with a fine glass rod for 3 min to resolubilize the dried iodinated ester. 
0.5 ml of Clq was then added to the chilled mixture and it was stirred 
for 3 min. T he reaction mixture was incubated on ice for 3 hr and 
dialyzed against 500 ml of the sodium chloride buffer at 4 oc for 48 hr 
with 3 changes of dialysis fluid . Specific activi ty of the 12''1-Clq used in 
these assays was 0.1-0.2 ~tCi/~tg Clq. 
120!-Clq Binding Assay (Polyethyleneglycol Precipitation) 
The Clq binding assay was performed as previously described [9]. In 
brief, 0.2 ml of test serum was incubated with 0.4 ml of Na2 EDTA (0.2 
M, pH 7.5) for 30 min at 37°C. Two hundred nanograms of 125I-Clq was 
added to the mixture followed by 1 ml of 4% (wt/vol) polyethylene 
glycol (PEG) (carbowax, m.w. 6,000, Fisher Scientific Co., Fairlawn, 
NJ) to make a final concentration of 2.5% PEG. After incubating the 
mixture on ice for 1 hr it was centrifuged at 1,000 g for 20 min. The 
supernatant was decanted and the residua l radioactivity was counted. 
Results are expressed as percent of 12''I precipitated. All samples were 
tested in duplicate. A standard normal human serum (NHS) was used 
as a negative cont rol in each assay. Positive controls consisted of serial 
dilutions of heat aggregated human gamma globulin (HGG) (Miles 
Laboratories, Inc. , Kankakee, IL) added to a standard normal human 
serum. Test sera were stored at - 40°C. The sera of normal volunteers 
served as contro ls. The upper 95% confidence limit of C1q BA in the 
cont rol population was 10%. 
R eduction Studies 
T he effect of su lfhydryl reducing agents on the 125I-Clq binding assay 
was determined by adding 2-mercaptoethanol (2-ME) in 0.2 M NaCl, 
0.1 M Tris buffer, pH 8.3, to NHS containing serial dilutions of HGG, 
in order to give final concentrations of 10- 1 M, 5 X 10- 2 M , or 10- 2 M 2-
ME. The mixture was then incubated for 20 min at room temperature 
and tested for 12f'I-Clq binding as indicated in the text. Test sera from 
MC patients were subsequently pretreated with 10- 2 M 2-ME and then 
examined for 125I-Clq binding activity (BA) and RF without removal of 
2-ME. 
Abso1ption studies 
Sepharose 4B-CL protein A beads (Pharmacia Fine Chemicals, Pis-
cataway, NJ) were allowed to swell in 0.15 M phosphate buffered saline 
(PBS), pH 7.4, washed 4 t imes a nd used to absorb certa in MC sera. 
Sera were incubated with swollen beads for 30 min at room tempera-
ture. The beads were washed 3 t imes with PBS and then treated with 
0.1 M HCI-glycine buffer, pH 3.0, for 15 min. The acidic protein eluates 
were immediately neutralized with 1 N NaOH and then dialyzed against 
PBS, pH 7.4 for 16 hr at 4°C. The eluates were tested for their ab ility 
to bind 125I-Clq and for content of HB,Ag and antibody to HB,Ag. 
Other Serologic Studies 
Hemolyt ic t itration of human C4 was performed as previously re-
ported [10]. CH50 titration was performed by the method of Mayer 
[11]. Human C3 was quantitated with commercially available immu-
nodiffusion plates (Behring Diagnostic). Hepatitis B surface antigen 
and antibody to the surface antigen were assayed using a commercially 
available radioimmunoassay (Abbott Labs) [7]. Rheumatoid factor was 
measured by the la tex fixation test [ 12]. 
Cryoprecipita tion 
Cryoprecipita tion of serum was carried out at 4°C for 96 hr. The 
serum was then spun at 1500 g for 10 min at 4°C. Isolated cryoprecip-
itates were washed serially with cold PBS un til no albumin could be 
detected by immunodiffusion and flll'th er characterized by immuno-
electrophoresis or fractionation as previously described [1]. 
Sucrose Density Ultracentrifugation 
Sucrose density grad ient studies were performed on protein A eluates 
of sera of patients with mixed cryoglobulinemia and of normals. The 
protein concentration of the eluates of the MC sera were adjusted with 
PBS to equal that of the eluates of normal sera . 200 microli ters of 
eluate was placed on 10-40% sucrose gradients in PBS pH 7.4. Gradients 
were spun at 50,000 rpm for 17 h.r at 4 oc in Beckman Ultracentrifuge 
model L2-65B using an SW65 rotor. 0.6 ml samples were collected from 
the bottom of the gradients. Normal human serum (NHS) diluted 1:5 
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was run concurrently with th e eluates and the position of lgG and IgM 
in the NHS gradients served as 7S and 19S markers. 
RESULTS 
125/-Clq Binding Assay 
All13 patients had elevated (>10%) 1201-Clq binding activity 
(BA) in fresh serum before cryoprecipitation, ranging from 39% 
to 83% (mean= 69%) (Fig 1) . After removal of cryoproteins by 
precipitation at 4 °C for 96 hr, 10 of the 13 sera still had 
increased 1251-Clq BA (mean Clq BA = 41%). However, all sera 
showed decrements in ClqBA after cryoprecipitation that 
ranged from minimal to marked (range 1% to 73%, mean dec-
rement= 28%) (Fig 2). The serum concentration of cryoprecip-
itate was measured in 10 patients and ranged from 7.7 mg% to 
300 mg%. There was no correlation between ClqBA and the 
amount of cryoprecipitate or between the decrease in ClqBA 
following cryoprecipitation and the amount of cryoprecipitate. 
Rheumatoid factor (RF) was present in all sera and ranged in 
titer from 80 to 32,768. There was no correlation between the 
amount of ClqBA and the titer of RF. 
Complement and Other Serologic Studies 
Hemolytic C4 and CH50 titers and antigenic C3 levels were 
performed on the sera of 9 patients (Fig 3). C4 levels were 
markedly depressed in 8 of 9 patients while CH50 levels were 
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FIG 2. T he effect of cryoprecipitat ion fo r 96 hr at 4 oc on '"'' 1-C lq 
BA in sera of 13 patients with mixed cryoglobulinemia. 
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FIG 3. Serum complement levels (CH,,o, C4 and C3) in 9 patients 
with mixed cryoglobu linemia. Cross hatched areas represent norma l 
ranges. 
somewhat decreased in 5 of 9 patients. T hree patients had 
minimally depressed serum C3 levels, 5 were normal and one 
patient had elevated serum C3. Analysis by Spearman rank 
correlation showed that CH50 levels were inversely correlated 
with ClqBA (rho= -.667, p < 0.025) bu t there was no significant 
association between C3 or C4 levels and ClqBA. 
Hepatitis B smface antigen (HBsAg) was detected in the sera 
of 4 patients and antibody to HBsAg was found in the sera of 
3 patients. The serum of one pa tient contained both antibody 
and antigen. 
Reduction Studies 
2-ME, a strong disulfide reducing agent, dissociates 198 1gM 
into subunits. T he effect of 10- 2 M2-ME on the 1251-Clq BA and 
RF was examined in 7 patients with MC. This final concentra-
t ion of 2-ME has been previously shown to have a minimal 
inhibitory effect on the 1251-Clq binding assay, but is capable of 
eliminating 1gM RF [13]. 2-ME treatment of 7 MC sera resulted 
in minimal decrements in Clq BA in 5 sera and moderate 
decrements in 2 sera (overall mean decrease = 11%). However 
RF ranging in titer from 512 to 32,768 was totally eliminated in 
all 7 of the sera in which it was present (Fig 4). 
Protein A Absorption Studies 
Protein A is a staphylococcal cell surface component with a 
marked affinity for IgG (subclasses 1, 2 and 4). The effect of 
solid phase protein A absorption on the ClqBA in the sera of 9 
patients with MC was examined. All sera initia lly had high 
ClqBA (45%-83%). Following absorption with solid phase pro-
tein A, the ClqBA of all sera fell (mean decrement 55%) and in 
7 of the 9 sera the immune complex-like material was com-
pletely removed by protein A absorption (Table). 
Following incubation in serum conta ining Clq binding activity 
6 protein A sepharose conjugates were washed and eluates of 
the absorbed protein were prepared. Abnormal elevations of 
ClqBA (20-60%) could be induced in normal human serum by 
the add ition of neutral ized protein A eluates of these MC sera. 
Cont rols consisting of acid eluates of normal sera absorbed with 
protein A sepharose showed no elevation of ClqBA. 
T he sera and protein A eluates of 6 MC patients were 
examined for the presence of HB,Ag and antibody to HB,Ag. 
T he sera of 2 patients conta ined HBsAg and one patient con-
tained antibody to HB,Ag. When the protein A eluates of these 
patients' sera were similarly studied it was found that the 
eluates of the 2 patients with HB,Ag in their serum also 
contained significant t iters ofHB,Ag by rad ioimmunoassay and 
that the patient with antibody to HBsAg also had large amounts 
of this antibody in the protein A eluate of her serum. The 3 
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300 LAWLEY ET AL 
Effect of solid-phase protein-A absorption on '2''1-Cl" binding activity 
in sera of patients with mixed cryoglobulinemia 
Patient Cl,, SA-Pre protein A CI,, BA-Post protein A absorption absorption 
1 45% 4% 
2 79% 4% 
3 58% 5% 
4 83% 49% 
5 33% 15% 
6 71% 5% 
7 65% 7% 
8 82% 5% 
9 80% 4% 
MC patients who did not have HB,Ag or antibody to HB,Ag in 
their sera did not have evidence of either in their eluates. 
Sucrose Density Gradient Studies 
Protein A eluates of 2 patients with MC and 2 normals were 
fractionated on continuous 10-40% sucrose gradients and the 
sedimentation characteristics of the contained IgG examined. 
In both of the instances the protein A eluates of MC sera 
contained IgG which sedimented not only as 7S molecules but 
also 8S-19S molecules. Gradients of eluates of NHS revealed 
only 7S-IgG. IgM was not identified in the protein A eluates of 
either MC sera or NHS. 
DISCUSSION 
Mixed cryoglobulinemia is a clinical syndrome of unknown 
etiology in which circulating immune complexes are thought to 
play an important pathogenetic role. All MC patients have, by 
definition, cryoglobulins in their sera, but until now newer more 
sensitive methods of immune complex detection have not been 
applied to this disease. 
The C1q binding assay is capable of detecting immune com-
plexes which contain either IgG (subclasses IgG~o IgG2, IgG3 ) or 
IgM as the antibody moiety. It is a sensitive and highly repro-
ducible assay [14,15]. Although substances such as DNA and 
endotoxin are capable of binding C1q, they do not cause false 
positive results in the C1q binding assay because they do not 
precipitate in the concentration of polyethylene glycol utilized 
[16]. In this study we have confirmed by means of the 125 I-C1q 
binding assay that the sera of MC patients do indeed contain 
large amounts of soluble ·immune complexes. We have also 
demonstrated that the sera of these patients also contain sub-
stantial amounts of soluble immune complex-like material 
which is not cryoprecipitable, since most of these patients' sera 
still had abnormally elevated C1qBA after separation of 96 hr 
cryoprecipitates from the sera. All of the patients had signs and 
symptoms of immune complex disease including necrotizing 
vasculitis, arthritis and a1thralgias, glomeruloneph1·itis and hy-
pocomplementemia. However, except for the correlation be-
tween serum CH50 levels and C1qBA, no clear associations 
could be found between the clinical and laboratory parameters 
of disease and the amount of immune complex-like material 
present in the sera before or after cryoprecipitation. 
Since it was known that all the sera contained high titer RF 
and that RF was detectable in all of the cryoglobulins, we 
considered the possibility that most of the C1qBA in these sera 
was due to IgM-IgG RF complexes. In order to examine this 
issue we performed immunochemical analyses of these sera. 
Since 2-ME will dissociate pentameric 19S IgM into its 7S 
subunits and hence destroy RF activity, we sought direct evi-
dence for the presence of immune complexes distinct from 19S 
lgM RF complexes by treating MC sera with 2-ME and analyz-
ing the sera for RF and 125 I-C1qBA before and after. Because 
2-ME is also capable of inhibiting complement binding to IgG 
containing immune complexes, we chose a concentration which 
displayed minimal inhibitory effect on the C1q binding assay. 
RF activity was completely eliminated in all cases, but the 
ClqBA was only minimally decreased in 5 of 7 cases. This 
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suggested that most of the C1q binding material was distinct 
from 19S IgM RF complexes. To investigate fmther this pos-
sibility we pe1formed experiments utilizing solid phase protein 
A whose affinity is predominantly for IgG. The fact that the 
C1qBA of MC sera could be rn·amatically reduced in all in-
stances by protein A absorption and decreased to background 
levels in most sera, strongly suggested that much of the C1q 
binding material in these sera contained IgG. Indeed by eluting 
this bound material from the solid phase protein A and adding 
it to normal human serum known to have normal C1qBA 
strikingly abnormal elevations in C1qBA (up to 60%) were 
induced with every eluate tested. This strongly suggested that 
the vast majority of the C1q binding material in these sera was 
in the form of lgG immune complexes. The size of the immune 
complexes was investigated by examining the sedimentation 
profile of the IgG contained in the protein A eluates after it had 
been subjected to sucrose density gradient ultracentrifugation. 
The IgG in the eluates of MC sera sedimented in a broad band 
from 7S to 19S while that of NHS was restricted to 7S. The 
presence of "heavy" IgG in the protein A eluates of MC sera 
and the lack of associated IgM again indicates that lgG immune 
complexes are present in the sera of patients with MC. 
· Since it has been shown by Levo eta] that patients with MC 
have a high incidence of liver disease and that many MC 
· patients have either HB,Ag or antibody to HB,Ag in their sera 
or cryoprecipitates [7], we examined the protein A eluates of 6 
patients with MC, 2 of whom were known to have HB.Ag in 
their serum and one of whom had serum antibody to HB,Ag. 
The 2 individuals who were HB,Ag positive also had HB,Ag in 
theu· protein A eluates while the patient with antibody to 
HB.Ag also contained antibody in the eluate. The fact that 
protein A has a high affinity for IgG antibody, that these eluates 
contain immune complex-like material and that a suspected 
antigen is present in this material, supports the impression that 
HB.Ag does indeed represent an antigen in the immune com-
plexes of some patients with MC. 
The question of whether sensitive immune complex assays 
such as the C1q binding assay and others will be of value in 
monitoring clinical disease activity awaits the performance of 
careful longitudinal studies utilizing multiple assay systems. It 
may be that certain subtypes of unmune complexes are partic-
ularly pathogenic because of their ability to persist in the 
circulation. Indeed Hamburger et al. have recently demon-
strated a striking association between the presence of renal 
disease in patients with MC and a defect in reticuloendothelial 
system clearance [17) but failed to note a relationship to the 
amount of cryoglobulin, C1qBA or the degree of complement 
depression. This observation raises the possibility that certain 
subtypes of the noncryoprecipitable complexes may play a 
major role in initiating tissue damage. Further characterization 
of the types and amounts of immune complexes in the clinical 
subgroups of MC may be extremely informative. 
. In summary it appears that patients with MC have cu·culating 
rmmune complexes which are noncryoprecipitable in addition 
to those that are. These immune complexes are in most cases 
distinct from 198 IgM RF complexes, have lgG as the predom-
inant antibody and in some cases may have HB,Ag as the 
antigen moiety. 
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